Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (2365)	8/3/1999 5:50:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 2539

Arthritis pill outsells Viagra Last Update: 0:45 AM ET Aug 3, 1999 NEW YORK (AP) -- Viagra grabbed the headlines, became the topic for jokes on late night talk shows and made it acceptable to talk about male impotence. But while sex sells, the promise of pain relief, apparently, is what really makes for hot sales. Celebrex, a new pill that offers arthritis pain relief with less stomach irritation, has surpassed Viagra to become the fastest selling new drug ever. Celebrex, which was introduced in January, sold 6.86 million prescriptions during its first six months on the market, compared with 6.05 million for Viagra during its first six months, according to IMS Health, a research company. Celebrex began to outpace Viagra in prescriptions after four months. Sales of Celebrex in the first six months added up to about $600 million, said Monsanto (MTC: news, msgs), which co-markets the drug with Pfizer (PFE: news, msgs). In comparison, Viagra had $552 million in sales its first six months beginning in April 1998. Viagra is also made by Pfizer. Both Celebrex and Viagra serve huge markets. Arthritis effects about 37 million Americans; impotence affects 30 million men. But Celebrex has some key advantages. Many arthritis sufferers need pain relief every day. Men only need to take Viagra when they plan to have sex. Further, Celebrex users also have largely stayed with the drug. Industry experts said thousands of men were inspired by the hype surrounding Viagra, and tried it only as an experiment. "A significant amount of usage of Viagra was recreational and after a while those users got over the novelty of it," said Jack Lamberton, an analyst with HSBC Securities. Another big factor is insurance. Most insurance programs consider Viagra a lifestyle medication, and as a result either don't cover it or severely restrict coverage to a few pills per month. As a treatment for a serious, chronic disease, Celebrex enjoys greater insurance coverage. Without coverage, patients may balk at paying the $2.42 a day for Celebrex or $8 per Viagra pill, industry analysts said. Celebrex was the first in a class of new arthritis drugs called cox-2 inhibitors, which target an enzyme called cyclo-oxegenase-2 that causes inflammation. Unlike earlier drugs, cox-2 inhibitors don't act against a second enzyme, cyclo-oxegenase-1, which protects the stomach lining. Ulcers, stomach bleeding and other gastrointestinal side effects are a major problem with many painkillers, such as ibuprofen or aspirin, causing an estimated 16,500 deaths a year. While tests show that cox-2 inhibitors may cause fewer ulcers than other drugs, the Food and Drug Administration still required Monsanto to put the same warning about side effects on Celebrex's label as the older drugs. Monsanto is conducting further tests to confirm that Celebrex is safer. Ed Sudol, of Sleepy Hollow, N.Y,. has taken medications for his rheumatoid arthritis for 30 years. When he heard about Celebrex, he immediately asked his doctor for it. Though Sudol has suffered no stomach problems from the other drugs, he also takes an ulcer medication just in case. Sudol said he can stop taking that medication because he feels more confident he is not hurting his stomach. "It's all about quality of life," he said. Both Celebrex and Viagra are expected to surpass $1 billion in worldwide sales in 1999 as they are introduced in new countries. But analysts then expect Celebrex sales to continue climbing to nearly $4 billion in 2002, while Viagra grows more slowly to about $1.5 billion. Marketers note that despite its rapid launch, Celebrex still has just 20 percent of the market for arthritis drugs. Many people still rely on generic or over-the-counter medicines. Does carrying the mantle of the hottest selling new drug really matter in the long run? "It's great for publicity's sake and the company that introduced it," Lamberton said. "It helps keep the drug in the public eye." cbs.marketwatch.com